Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias
Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …
Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease
Background: The only conclusive way to diagnose Alzheimer's is to carry out brain autopsy
of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other …
of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other …
Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment …
GD Rabinovici, C Gatsonis, C Apgar, K Chaudhary… - Jama, 2019 - jamanetwork.com
Importance Amyloid positron emission tomography (PET) detects amyloid plaques in the
brain, a core neuropathological feature of Alzheimer disease. Objective To determine if …
brain, a core neuropathological feature of Alzheimer disease. Objective To determine if …
Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia
Abstract Since 1989, four Canadian Consensus Conferences on the Diagnosis and
Treatment of Dementia (CCCDTD) have provided evidence‐based dementia guidelines for …
Treatment of Dementia (CCCDTD) have provided evidence‐based dementia guidelines for …
Quantification of amyloid PET for future clinical use: a state-of-the-art review
Amyloid-β (Aβ) pathology is one of the earliest detectable brain changes in Alzheimer's
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
disease (AD) pathogenesis. The overall load and spatial distribution of brain Aβ can be …
[HTML][HTML] Diagnostic biomarkers of amyloid and tau pathology in Alzheimer's disease: an overview of tests for clinical practice in the United States and Europe
Amyloid and tau biomarkers for Alzheimer's disease are widely recognized diagnostic tools
for the identification of Alzheimer's disease pathology antemortem and are recommended by …
for the identification of Alzheimer's disease pathology antemortem and are recommended by …
Brain SPECT as a biomarker of neurodegeneration in dementia in the era of molecular imaging: still a valid option?
R Ferrando, A Damian - Frontiers in Neurology, 2021 - frontiersin.org
Biomarkers are playing a progressively leading role in both clinical practice and scientific
research in dementia. Although amyloid and tau biomarkers have gained ground in the …
research in dementia. Although amyloid and tau biomarkers have gained ground in the …
PET and SPECT imaging of the brain: history, technical considerations, applications, and radiotracers
KM Davis, JL Ryan, VD Aaron, JB Sims - Seminars in Ultrasound, CT and …, 2020 - Elsevier
Advances in nuclear medicine have revolutionized our ability to accurately diagnose
patients with a wide array of neurologic pathologies and provide appropriate therapy. The …
patients with a wide array of neurologic pathologies and provide appropriate therapy. The …
Amyloid PET imaging in clinical practice
MA Kolanko, Z Win, F Loreto, N Patel, C Carswell… - Practical …, 2020 - pn.bmj.com
Amyloid positron emission tomography (PET) imaging enables in vivo detection of brain Aβ
deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is …
deposition, one of the neuropathological hallmarks of Alzheimer's disease. There is …
18F-FDG is a superior indicator of cognitive performance compared to 18F-florbetapir in Alzheimer's disease and mild cognitive impairment evaluation: a global …
Background: 18 F-Fluorodeoxyglucose (18 F-FDG) positron emission tomography (PET) and
18 F-florbetapir PET are approved neuroimaging biomarkers for the Alzheimer's disease …
18 F-florbetapir PET are approved neuroimaging biomarkers for the Alzheimer's disease …